{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:14:23Z","timestamp":1788736463545,"version":"build-2803163510"},"reference-count":15,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:p>Bleomycin has progressively been used to treat low-flow vascular malformations in children. No significant systemic side effects have been reported in large series after low doses, but some authors are still concerned about its use. We report a case of a severe acute lung toxicity after a low dose of a second bleomycin intralesional injection in a 5-year-old girl. She had no risk factors and presented a cervical low-flow venous malformation. Twenty-four hours after this second administration, she presented with fever and respiratory distress. A chest radiograph showed bilateral opacities and computerized tomography revealed extensive and diffuse lung ground-glass opacities. The patient started to receive intravenous methylprednisolone, but she experienced progressively increased dyspnea, and montelukast was added. She improved and was discharged from the hospital without oxygen support, with montelukast and prednisolone for tapering doses during months. Five months after onset, the patient is developing well, is active, and walks and talks without dyspnea. A new low-dose computed tomography shows improvement in radiologic findings. This is the second case of pulmonary toxicity observed in a child after bleomycin intralesional administration, and the first reported after the lowest dose of this drug to date (7 mg: 0.28 mg\/kg; 10 U: 0.4 U\/kg). A delay in the diagnosis and treatment of this complication can be fatal. Any physician who treats these patients must be alert and consider this complication in children with respiratory symptoms after bleomycin sclerotherapy. Early detection of pulmonary toxicity would allow prompt therapy and could avoid pulmonary damage.<\/jats:p>","DOI":"10.1542\/peds.2016-1787","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T03:30:44Z","timestamp":1513827044000},"source":"Crossref","is-referenced-by-count":44,"title":["Acute Lung Toxicity After Intralesional Bleomycin Sclerotherapy"],"prefix":"10.1542","volume":"141","author":[{"given":"Ana","family":"M\u00e9ndez-Echevarr\u00eda","sequence":"first","affiliation":[{"name":"Departments of General Pediatrics and Infectious and Tropical Diseases,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Fernandez-Prieto","sequence":"additional","affiliation":[{"name":"Radiology, Interventional Neuroradiology Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"de la Serna","sequence":"additional","affiliation":[{"name":"Pediatric Pneumology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Lopez-Gutierrez","sequence":"additional","affiliation":[{"name":"Pediatric Surgery, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Parron","sequence":"additional","affiliation":[{"name":"Pediatric Radiology Section, Hospital La Paz, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a","family":"Marin-Aguilera","sequence":"additional","affiliation":[{"name":"Radiology, Interventional Neuroradiology Unit,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Calvo","sequence":"additional","affiliation":[{"name":"Departments of General Pediatrics and Infectious and Tropical Diseases,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"issue":"2","key":"2021121018311136100_B1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ppul.21139","article-title":"Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation.","volume":"45","author":"Atwa","year":"2010","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"2021121018311136100_B2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pupt.2005.01.007","article-title":"Bleomycin lung toxicity: who are the patients with increased risk?","volume":"18","author":"Azambuja","year":"2005","journal-title":"Pulm Pharmacol Ther"},{"issue":"8","key":"2021121018311136100_B3","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1097\/MPH.0000000000000424","article-title":"Bleomycin-associated lung toxicity in childhood cancer survivors.","volume":"37","author":"Zorzi","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"2021121018311136100_B4","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/1078155215574294","article-title":"The role of screening and monitoring for bleomycin pulmonary toxicity.","volume":"22","author":"Shippee","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"2021121018311136100_B5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bjps.2015.10.045","article-title":"Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents.","volume":"69","author":"Horbach","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"issue":"2","key":"2021121018311136100_B6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/2000656X.2014.951051","article-title":"Intralesional bleomycin injection in management of low flow vascular malformations in children.","volume":"49","author":"Mohan","year":"2015","journal-title":"J Plast Surg Hand Surg"},{"issue":"5","key":"2021121018311136100_B7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/SCS.0000000000000900","article-title":"Appraisal of efficacy and safety of intralesional injection of high concentration of bleomycin A5 for treatment of huge macrocystic lymphatic malformations in cervical region.","volume":"25","author":"Xu","year":"2014","journal-title":"J Craniofac Surg"},{"issue":"5","key":"2021121018311136100_B8","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1097\/PRS.0b013e31820e923c","article-title":"Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit.","volume":"127","author":"Sainsbury","year":"2011","journal-title":"Plast Reconstr Surg"},{"issue":"6","key":"2021121018311136100_B9","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1007\/s00270-014-0932-z","article-title":"Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation.","volume":"37","author":"Chaudry","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"2021121018311136100_B10","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PRS.0000000000001924","article-title":"Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis.","volume":"137","author":"Horbach","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"1","key":"2021121018311136100_B11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.otc.2014.09.004","article-title":"Head and neck vascular lesions.","volume":"48","author":"Hoff","year":"2015","journal-title":"Otolaryngol Clin North Am"},{"issue":"6","key":"2021121018311136100_B12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/bph.12355","article-title":"Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations.","volume":"170","author":"Zhang","year":"2013","journal-title":"Br J Pharmacol"},{"key":"2021121018311136100_B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1465-9921-7-137","article-title":"Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.","volume":"7","author":"Failla","year":"2006","journal-title":"Respir Res"},{"issue":"2","key":"2021121018311136100_B14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1164\/ajrccm.165.2.2104050","article-title":"Protection from pulmonary fibrosis in leukotriene-deficient mice.","volume":"165","author":"Peters-Golden","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"2021121018311136100_B15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/bja\/aen395","article-title":"General anaesthesia for intralesional bleomycin therapy of vascular malformations: initial 3 yr experience.","volume":"102","author":"Kessell","year":"2009","journal-title":"Br J Anaesth"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1787\/1065881\/peds_20161787.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1787\/1065881\/peds_20161787.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:27:32Z","timestamp":1639182452000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/141\/1\/e20161787\/37711\/Acute-Lung-Toxicity-After-Intralesional-Bleomycin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,1]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-1787","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,1]]},"article-number":"e20161787"}}